GLP-1 receptor agonists in neurodegenerative diseases: translational evidence and clinical potential

Introduction

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes and obesity, are increasingly being explored as candidate disease-modifying therapies for neurodegenerative disorders. Interest in this drug class has grown because neurodegeneration shares several pathological processes that GLP-1RAs may influence, including impaired insulin signaling, mitochondrial dysfunction, oxidative stress, neuroinflammation, protein aggregation, and synaptic loss. Despite strong biological plausibility, the clinical relevance of these effects remains under active investigation. [1]

Objectives of the study This review aimed to evaluate the translational evidence supporting GLP-1RAs as potential therapies for neurodegenerative diseases. The authors sought to summarize mechanistic data, preclinical findings, and emerging clinical evidence across major conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and ischemic stroke-related neuroinjury. A further objective was to assess whether the current evidence is sufficient to justify therapeutic repositioning of GLP-1RAs in neurology. [1]

Methods

The article is a narrative translational review that synthesizes experimental and clinical literature on GLP-1RAs in neurodegeneration. The authors analyze findings from cell-based studies, animal models, biomarker studies, observational human data, and early clinical trials. The review focuses on biological mechanisms and disease-specific effects rather than on a single intervention trial or meta-analysis. Particular attention is given to pathways involving cAMP/PKA signaling, PI3K/Akt, AMPK, CREB, NF-κB inhibition, mitochondrial homeostasis, autophagy, synaptic plasticity, and neuroinflammatory modulation. Evidence was organized across disease categories to compare consistency, limitations, and translational potential. [1]

Results

Across preclinical studies, GLP-1RAs showed broad neuroprotective actions. These included reduced protein aggregation, lowered tau phosphorylation, reduced amyloid-β burden, attenuation of α-synuclein pathology, partial mitigation of mutant huntingtin aggregation, and possible effects on TDP-43 pathology. In addition, GLP-1RAs improved mitochondrial function, enhanced autophagy, reduced oxidative injury, and preserved synaptic integrity in multiple disease models. Mechanistically, they appeared to suppress neuroinflammation through downregulation of pro-inflammatory cytokines and inhibition of NF-κB signaling, while also supporting neuronal survival through CREB- and Akt-mediated pathways.Human evidence is more limited but increasingly suggestive. Observational studies indicate that GLP-1RA exposure may be associated with a lower risk of incident Parkinson’s disease, Alzheimer’s dementia, and other neurodegenerative outcomes. However, these findings are not yet definitive, and causality cannot be established from current data. Early interventional trials have produced mixed results, with some showing signal of benefit and others failing to demonstrate clear clinical efficacy. Overall, the translational gap between robust preclinical results and uncertain clinical outcomes remains substantial. [1]

Conclusions GLP-1 receptor agonists represent a promising and biologically plausible class of disease-modifying agents for neurodegenerative disorders. Their pleiotropic effects on metabolism, inflammation, mitochondrial function, and protein homeostasis provide a strong mechanistic rationale for further study. Nevertheless, current clinical evidence is insufficient to support routine use in neurodegenerative disease outside research settings. Well-designed randomized controlled trials, biomarker-guided studies, and target-engagement analyses are needed to determine whether these agents can deliver meaningful clinical benefit in humans. [1]

References

Athauda, D., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026). The promise of GLP-1 receptor agonists for neurodegenerative diseases. The Journal of clinical investigation, 136(4), e194745. https://doi.org/10.1172/JCI194745